Pharmaceutical News

RSS

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.

23 Feb 2013

Widespread ART coverage can reduce risk of HIV infection, increase life expectancy of general population, studies show

"An intensive campaign to combat HIV/AIDS with costly antiretroviral drugs in rural South Africa has increased life expectancy by more than 11 years and significantly reduced the risk of infection for healthy individuals, according to new research," the Los Angeles Times reports.

23 Feb 2013

Viewpoints: Other GOP governors should note what Scott wrangled out of HHS; Curbs on painkillers need to be tougher

Those governors who earlier embraced ObamaCare's Medicaid expansion - here's looking at you, Jan Brewer - might be feeling a little cheated. If only they had held out a bit longer, they might have been able to obtain something from the Obama administration in return, as Florida's Rick Scott purports to have done.

23 Feb 2013

FDA approves Lupin Pharmaceuticals' SUPRAX for Oral Suspension

Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received approval for SUPRAX (Cefixime) for Oral Suspension, 500 mg/5mL from the United States Food and Drugs Administration (FDA).

23 Feb 2013

New drug to safeguard against epidemic and pandemic flu strains

CSIRO scientists have helped to design a new drug to safeguard against epidemic and pandemic flu strains – as published in Science today.

22 Feb 2013

Marine-based active substances show promise against multiple myeloma

There is fierce competition in the ocean habitat. In order to survive there, marine organisms defend themselves against their rivals using an entire arsenal of chemical weapons. With the help of these substances they attack hostile cells, overcome their defence system and thus are interesting active substance candidates for cancer research.

22 Feb 2013

Physicians afraid to give thrombolytic drugs to pulmonary embolism patients for good reason

When doctors encounter a patient with a massive pulmonary embolism, they face a difficult choice: Is it wise to administer a drug that could save the patient's life, even though many people suffer life-threatening bleeding as a result? Based on new findings published in the American Journal of Medicine, Michigan State University researchers are answering that question in no uncertain terms.

22 Feb 2013

New molecular compounds can kill the influenza virus

Simon Fraser University virologist Masahiro Niikura and his doctoral student Nicole Bance are among an international group of scientists that has discovered a new class of molecular compounds capable of killing the influenza virus.

22 Feb 2013

Research on animal models demonstrates that antidepressants are not a cure as such

We should reconsider how we use antidepressants more effectively. The latest studies have shown that antidepressants restore the capacity of certain areas of the brain to repair abnormal neural pathways. According to neuroscientist Eero Castrén, the recipient of EUR 2.5 million of ERC funding, recovery requires redirection of these pathways through practice, rehabilitation or therapy.

22 Feb 2013

Janssen submits simeprevir regulatory application in Japan to treat HCV

Medivir AB today announced that its partner Janssen now has submitted a regulatory application to the Japanese Ministry of Health & Welfare authorities seeking approval for simeprevir, administered with pegylated interferon (Peg-IFN) and ribavirin (RBV) for the treatment of genotype 1 chronic hepatitis C patients who are treatment naïve, prior non responders or relapsed following treatment with Peg-IFN with or without RBV.

22 Feb 2013

Isotretinoin does not increase risk of inflammatory bowel disease

Doctors should not be discouraged from prescribing isotretinoin to adolescents for inflammatory acne, according to a new study by Canadian and U.S. scientists showing the drug does not increase the risk of inflammatory bowel disease (IBD).

22 Feb 2013

Scopolamine can help boost effectiveness of exposure therapy for anxiety disorders

The drug scopolamine has been used to treat a variety of conditions, including nausea and motion sickness. A new study by UCLA life scientists suggests that it may also be useful in treating anxiety disorders.

22 Feb 2013

Researchers determine that neuroblastoma is sensitive to BET bromodomain inhibitors

Neuroblastoma, the most common malignant tumor of early childhood, is frequently associated with the presence of MYCN amplification, a genetic biomarker associated with poor prognosis. Researchers have determined that tumors containing MYCN amplification are sensitive to a new class of drugs, BET bromodomain inhibitors.

22 Feb 2013

Scientists uncover atomic structure of dermcidin

An international team of scientists has discovered how an important natural antibiotic called dermcidin, produced by our skin when we sweat, is a highly efficient tool to fight tuberculosis germs and other dangerous bugs.

22 Feb 2013

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen, immune globulin intravenous [human].

21 Feb 2013

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “auriclosene” (pronounced awr-rih-CLO-zeen) for the Company’s lead Aganocide® compound NVC-422.

21 Feb 2013

Eliminating insurance co-payments can improve medication adherence and management of diabetes

Reducing financial barriers to medication access—a strategy known as value-based insurance design (VBID)—can improve medication adherence and management of chronic diseases such as diabetes.

21 Feb 2013

Imatinib can relieve and slow down progression of multiple sclerosis

A drug that is currently used for cancer can relieve and slow down the progression of the autoimmune disease multiple sclerosis (MS) in rats, according to a new study published in PLOS ONE.

21 Feb 2013

Omega-3 emulsions can decrease brain tissue damage following stroke

Triglyceride lipid emulsions rich in an omega-3 fatty acid injected within a few hours of an ischemic stroke can decrease the amount of damaged brain tissue by 50 percent or more in mice, reports a new study by researchers at Columbia University Medical Center.

21 Feb 2013

Resveratrol may protect against hearing and cognitive decline

Resveratrol, a substance found in red grapes and red wine, may have the potential to protect against hearing and cognitive decline, according to a published laboratory study from Henry Ford Hospital in Detroit.

21 Feb 2013

Pharmaceutical News

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

Widespread ART coverage can reduce risk of HIV infection, increase life expectancy of general population, studies show

Viewpoints: Other GOP governors should note what Scott wrangled out of HHS; Curbs on painkillers need to be tougher

FDA approves Lupin Pharmaceuticals' SUPRAX for Oral Suspension

New drug to safeguard against epidemic and pandemic flu strains

Marine-based active substances show promise against multiple myeloma

Physicians afraid to give thrombolytic drugs to pulmonary embolism patients for good reason

New molecular compounds can kill the influenza virus

Research on animal models demonstrates that antidepressants are not a cure as such

Janssen submits simeprevir regulatory application in Japan to treat HCV

Isotretinoin does not increase risk of inflammatory bowel disease

Scopolamine can help boost effectiveness of exposure therapy for anxiety disorders

Researchers determine that neuroblastoma is sensitive to BET bromodomain inhibitors

Scientists uncover atomic structure of dermcidin

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

Eliminating insurance co-payments can improve medication adherence and management of diabetes

Imatinib can relieve and slow down progression of multiple sclerosis

Omega-3 emulsions can decrease brain tissue damage following stroke

Resveratrol may protect against hearing and cognitive decline

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News